Avacopan plus standard-of-care vs placebo plus standard-of-care in ANCA-associated vasculitis with severe kidney involvement

Phase 3, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) comparing Avacopan + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Renal recovery composite endpoint at week 52. Started Nov 2025; status: suspended.